Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SITC 2021 | Mechanism of action of evorpacept

Jong Chul Park • 13 Nov 2021
SITC 2021
General Evorpacept

Jong Chul Park, MD, Harvard Medical School, Boston, MA, discusses the mechanism of action of evorpacept; a fusion protein designed to inhibit the CD47-SIRPα pathway on myeloid cells. This interview took place during the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C.

More from Jong Chul Park

2:03
ASPEN-03: evorpacept in combination with pembrolizumab in patients with advanced HNSCC
Jong Chul Park • 13 Nov 2021
3:37
Early results from ONCR-177-101: ONCR-177 alone or in combination with anti-PD-1 blockade
Jong Chul Park • 13 Nov 2021

Related Videos

1:56
Phase I trial of trastuzumab deruxtecan and neratinib in HER2-altered tumors
Haeseong Park • 8 Apr 2024
2:45
Remaining challenges in treating solid tumors with CAR-Treg therapy
Leonardo Ferreira • 8 Apr 2024
2:01
Engineering chimeric antigen receptor regulatory T cells for treating cancer
Leonardo Ferreira • 8 Apr 2024
0:59
What challenges are there in using CAR-T cells for solid tumors?
Leonardo Ferreira • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals